DL-SyringaresinolCAS# 1177-14-6 |
- (+)-Syringaresinol
Catalog No.:BCN7496
CAS No.:21453-69-0
- Syringaresinol
Catalog No.:BCN3042
CAS No.:487-35-4
- Episyringaresinol
Catalog No.:BCN7023
CAS No.:51152-20-6
- (-)-Syringaresinol
Catalog No.:BCN3417
CAS No.:6216-81-5
- (-)-Episyringaresinol
Catalog No.:BCN9229
CAS No.:6216-82-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1177-14-6 | SDF | Download SDF |
| PubChem ID | 100067 | Appearance | Powder |
| Formula | C22H26O8 | M.Wt | 418.4 |
| Type of Compound | Lignans | Storage | Desiccate at -20°C |
| Synonyms | Lirioresinol A | ||
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 4-[6-(4-hydroxy-3,5-dimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-3-yl]-2,6-dimethoxyphenol | ||
| SMILES | COC1=CC(=CC(=C1O)OC)C2C3COC(C3CO2)C4=CC(=C(C(=C4)OC)O)OC | ||
| Standard InChIKey | KOWMJRJXZMEZLD-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C22H26O8/c1-25-15-5-11(6-16(26-2)19(15)23)21-13-9-30-22(14(13)10-29-21)12-7-17(27-3)20(24)18(8-12)28-4/h5-8,13-14,21-24H,9-10H2,1-4H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. (+)-Syringaresinol shows inhibitory activity of Helicobacter pylori motility with the IC50 value is 50 microg/ml. 2. (-)-Syringaresinol has been reported to potently inhibit the proliferation of human promyelocytic HL-60 cells through G 1 arrest and induction of apoptosis, suggests that it may be a potential chemotherapeutic agent for the treatment of cancer. 3. Syringaresinol induces vasorelaxation by enhancing NO production in endothelial cells via two distinct mechanisms, phosphatidylinositol 3-kinase/Akt- and (PLC)/Ca2+/CaMKKβ -dependent eNOS phosphorylation and Ca(2+)-dependent eNOS dimerization. 4. Syringaresinol can protect against hypoxia/reoxygenation-induced cardiomyocytes injury and death by destabilization of HIF-1α in a FOXO3-dependent mechanism. |
| Targets | Antifection | PI3K | Akt | Calcium Channel | NOS | HIF | NO |
DL-Syringaresinol Dilution Calculator
DL-Syringaresinol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.3901 mL | 11.9503 mL | 23.9006 mL | 47.8011 mL | 59.7514 mL |
| 5 mM | 0.478 mL | 2.3901 mL | 4.7801 mL | 9.5602 mL | 11.9503 mL |
| 10 mM | 0.239 mL | 1.195 mL | 2.3901 mL | 4.7801 mL | 5.9751 mL |
| 50 mM | 0.0478 mL | 0.239 mL | 0.478 mL | 0.956 mL | 1.195 mL |
| 100 mM | 0.0239 mL | 0.1195 mL | 0.239 mL | 0.478 mL | 0.5975 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- LY 255283
Catalog No.:BCC7290
CAS No.:117690-79-6
- Agomelatine hydrochloride
Catalog No.:BCC4210
CAS No.:1176316-99-6
- 3-Cyano-7-ethoxycoumarin
Catalog No.:BCC7979
CAS No.:117620-77-6
- 16-Oxocleroda-3,13E-dien-15-oic acid
Catalog No.:BCN7286
CAS No.:117620-72-1
- 1-Hydroxy-1-(4-hydroxy-2-methoxyphenyl)-3-(4-hydroxyphenyl)propan-2-one
Catalog No.:BCN1607
CAS No.:117614-84-3
- 6-Hydroxymethylherniarin
Catalog No.:BCN3573
CAS No.:117597-79-2
- Coronarin E
Catalog No.:BCN6052
CAS No.:117591-81-8
- Calpeptin
Catalog No.:BCC2351
CAS No.:117591-20-5
- DMXAA (Vadimezan)
Catalog No.:BCC3644
CAS No.:117570-53-3
- threo-6'-Hydroxyustusolate C
Catalog No.:BCN6930
CAS No.:1175543-07-3
- Ustusolate E
Catalog No.:BCN7789
CAS No.:1175543-06-2
- 2alpha,9alpha,11-Trihydroxy-6-oxodrim-7-ene
Catalog No.:BCN7741
CAS No.:1175543-03-9
- Laxogenin
Catalog No.:BCN8434
CAS No.:1177-71-5
- Dexamethasone acetate
Catalog No.:BCC4775
CAS No.:1177-87-3
- Doramectin
Catalog No.:BCC1536
CAS No.:117704-25-3
- CKI 7 dihydrochloride
Catalog No.:BCC5614
CAS No.:1177141-67-1
- (R)-(+)-Blebbistatin
Catalog No.:BCC7195
CAS No.:1177356-70-5
- Felbamate hydrate
Catalog No.:BCC4160
CAS No.:1177501-39-1
- Forsythoside I
Catalog No.:BCN6430
CAS No.:1177581-50-8
- N20C hydrochloride
Catalog No.:BCC7292
CAS No.:1177583-87-7
- SMANT hydrochloride
Catalog No.:BCC6254
CAS No.:1177600-74-6
- CGH 2466 dihydrochloride
Catalog No.:BCC7338
CAS No.:1177618-54-0
- Azithromycin Dihydrate
Catalog No.:BCC4631
CAS No.:117772-70-0
- Decumbenine C
Catalog No.:BCC8314
CAS No.:117772-89-1
Inhibition of Helicobacter pylori motility by (+)-Syringaresinol from unripe Japanese apricot.[Pubmed:16394533]
Biol Pharm Bull. 2006 Jan;29(1):172-3.
A methanol extract from unripe Japanese apricot showed inhibitory activity of Helicobacter pylori motility. Inhibitory compound 1 was isolated and identified as (+)-syringaresinol (1) by spectoroscopic means. (+)-Syringaresinol (1) inhibited >90% of the H. pylori motility at a concentration of 500 microg/ml and the IC50 value was 50 microg/ml.
(-)-Syringaresinol inhibits proliferation of human promyelocytic HL-60 leukemia cells via G1 arrest and apoptosis.[Pubmed:18486907]
Int Immunopharmacol. 2008 Jul;8(7):967-73.
We examined the effect of (-)-syringaresinol, a furofuran-type lignan isolated from Daphne genkwa, on cell cycle regulation in HL-60 human promyelocytic leukemia cells in vitro. (-)-Syringaresinol decreased the viability of HL-60 cells by inducing G(1) arrest followed by apoptosis in a dose- and time-dependent manner. The G(0)/G(1) phase of the cell cycle is regulated by cyclin-dependent kinases (Cdk), cyclins and cyclin-dependent kinase inhibitors (Cdki). We show by western blot analysis, that the (-)-syringaresinol-induced G(1) arrest was mediated through the increased expression of Cdki proteins (p21(cip1/waf1) and p27(kip1)) with a simultaneous decrease in cdk2, cdk4, cdk6, cyclin D(1), cyclin D(2), and cyclin E expression. The induction of apoptosis after treatment with (-)-syringaresinol for 24 h was demonstrated by morphological changes, DNA fragmentation, altered ratio of Bax/Bcl-2, cleavage of poly(ADP-ribose) polymerase and flow cytometry analysis. (-)-Syringaresinol also induced cytochrome c release and activation of caspase-3 and caspase-9. To our knowledge, this is the first time that (-)-syringaresinol has been reported to potently inhibit the proliferation of human promyelocytic HL-60 cells through G(1) arrest and induction of apoptosis. These findings suggest that (-)-syringaresinol may be a potential chemotherapeutic agent for the treatment of cancer.
